3 VM 1001 topical cream - CDA Research GroupAlternative Names: 3VM1001 cream - CDA Research Group
Latest Information Update: 09 Aug 2016
At a glance
- Originator CDA Research Group
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteoarthritis
Most Recent Events
- 09 Aug 2016 Phase-I clinical trials in Osteoarthritis in USA (Topical)